On November 27, 2019 Spherix Incorporated (Nasdaq: SPEX) reported that additional patent coverage has been granted by the United States Patent & Trademark Office to the patent portfolio being acquired by Spherix, in the field of pancreatic cancer (Press release, Spherix, NOV 27, 2019, https://www.prnewswire.com/news-releases/spherix-notes-additional-patent-coverage-granted-300966329.html [SID1234551766]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pancreatic cancer is the fourth most common cause of cancer-related deaths in the United States and the eighth worldwide. The Pancreatic Cancer Action Network Ô predicted that it will move from fourth to the second leading cause of cancer deaths in the US by 2020. US Patent number 10,463,684 was recently issued to the University of Texas at Austin and being assigned to Spherix as part of the CBM BioPharma, Inc. asset acquisition previously announced. The patent targets, among other things, pancreatic cancer with a different mechanism than the current standard of care. The compound has been shown to be effective in cancer cells that are resistant to the current standard of care in preclinical studies and expands the patent coverage for this compound.